IRIS
SANTORO, Armando
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 25.357
EU - Europa 5.080
AS - Asia 1.124
AF - Africa 821
SA - Sud America 54
Continente sconosciuto - Info sul continente non disponibili 42
OC - Oceania 19
Totale 32.497
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 25.040
FI - Finlandia 1.370
IE - Irlanda 1.115
NG - Nigeria 806
CN - Cina 559
IT - Italia 503
FR - Francia 499
DE - Germania 486
NL - Olanda 320
CA - Canada 310
SE - Svezia 273
GB - Regno Unito 209
TR - Turchia 184
IL - Israele 120
IN - India 108
BE - Belgio 88
RU - Federazione Russa 59
IR - Iran 33
CL - Cile 27
JP - Giappone 27
HK - Hong Kong 25
RO - Romania 25
A2 - ???statistics.table.value.countryCode.A2??? 21
EU - Europa 21
UA - Ucraina 20
AU - Australia 16
ES - Italia 14
PL - Polonia 13
GR - Grecia 12
SG - Singapore 12
CH - Svizzera 11
AR - Argentina 10
NO - Norvegia 10
IQ - Iraq 9
KR - Corea 9
AT - Austria 7
BD - Bangladesh 7
HU - Ungheria 7
PK - Pakistan 7
SI - Slovenia 7
TW - Taiwan 7
BR - Brasile 6
CO - Colombia 6
PT - Portogallo 6
MX - Messico 5
BG - Bulgaria 4
DK - Danimarca 4
EE - Estonia 4
EG - Egitto 4
ID - Indonesia 4
MK - Macedonia 4
AE - Emirati Arabi Uniti 3
CZ - Repubblica Ceca 3
LY - Libia 3
MD - Moldavia 3
ML - Mali 3
NZ - Nuova Zelanda 3
VN - Vietnam 3
ZA - Sudafrica 3
AL - Albania 2
JO - Giordania 2
MO - Macao, regione amministrativa speciale della Cina 2
PE - Perù 2
PH - Filippine 2
VE - Venezuela 2
CR - Costa Rica 1
HR - Croazia 1
MA - Marocco 1
MG - Madagascar 1
MY - Malesia 1
PA - Panama 1
RS - Serbia 1
UY - Uruguay 1
Totale 32.497
Salva come PNG Salva come JPEG
Città #
Wilmington 5.555
Chandler 4.577
San Mateo 2.030
Ann Arbor 1.548
Helsinki 1.367
Dublin 1.109
Leawood 944
Princeton 914
Lawrence 913
Benin City 804
Boardman 732
New York 552
Woodbridge 517
Fairfield 512
Ashburn 490
Paris 480
Shanghai 455
Amsterdam 302
Toronto 273
Milan 199
Kocaeli 181
Seattle 176
London 174
San Diego 164
Norwalk 119
Phoenix 96
Brussels 78
Falls Church 74
Pune 63
Redwood City 60
Monmouth Junction 50
Abbiategrasso 39
Beijing 39
Falkenstein 39
Redmond 37
Moscow 32
Des Moines 28
Andover 27
Cambridge 21
Ardabil 17
Frankfurt am Main 16
Clearwater 14
Houston 14
Zhengzhou 14
Genoa 13
Nanjing 13
Tappahannock 13
Tokyo 13
Sacramento 11
Winnipeg 11
Berlin 10
Cluj 9
Hanover 9
Montréal 9
Chennai 8
Chicago 8
Las Vegas 8
Singapore 8
Bengaluru 7
Central District 7
Gunzenhausen 7
Ljubljana 7
Montreal 7
Nanning 7
Raleigh 7
Saint Paul 7
San Jose 7
Taipei 7
Basiano 6
Hangzhou 6
Hasselt 6
Jacksonville 6
Kemerovo 6
La Canada Flintridge 6
Lormont 6
Munro 6
Athens 5
Bergamo 5
Chengdu 5
Cologno Monzese 5
Cupertino 5
Eden Prairie 5
Florence 5
Henderson 5
Lisbon 5
Santiago 5
Vancouver 5
Washington 5
Atlanta 4
Brisbane 4
Livorno 4
Sulaymaniyah 4
Tallinn 4
Vienna 4
Warsaw 4
Zwolle 4
Apo 3
Asahi 3
Augusta 3
Bamako 3
Totale 26.210
Salva come PNG Salva come JPEG
Nome #
KEYNOTE-204: Randomized, open-label, phase III study of pembrolizumab (pembro) versus brentuximab vedotin (BV) in relapsed or refractory classic Hodgkin lymphoma (R/R cHL) 143
Infections after T-replete haploidentical transplantation and high-dose cyclophosphamide as graft-versus-host disease prophylaxis 133
BMS-986148, an anti-mesothelin antibody-drug conjugate (ADC), alone or in combination with nivolumab demonstrates clinical activity in patients with select advanced solid tumors 91
Role of consolidation RT to bulky lesions of advanced Hodgkin lymphoma: results of FIL HD0801 trial 77
Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040 72
Three-week versus four-week schedule of cisplatin and gemcitabine: results of a randomized phase II study 70
Survival Outcome and Prognostic Factors After Pulmonary Metastasectomy in Sarcoma Patients A 18-Year Experience at a Single High-volume Referral Center 69
Tivantinib for Second-line Treatment of Advanced MET-High Hepatocellular Carcinoma: A Phase 3, Randomized, Placebo-Controlled Study (METIV-HCC) 69
18F-FDG PET and CT scan in the pre-operative evaluation of colorectal liver metastases treated with chemotherapy 67
An exploratory biomarker study in metastatic tumors from colorectal cancer patients treated with bevacizumab 66
Pharmacological inactivation of DNA repair to improve response to immunotherapy: The Arethusa trial in metastatic colorectal cancer 64
Carbon-11-methionine PET-CT as an imaging biomarker in brain gliomas eligible for surgery 64
Biological characteristics and long-term outcomes in node-negative breast cancer 63
Five-year results of the BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma 62
Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC) 61
A new human cell line, PDSS-26, from poorly differentiated synovial sarcoma, with unique chromosomal anomalies 61
Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin's lymphoma responding to prior salvage therapy 60
Activity of a specific inhibitor, gefitinib (Iressa, ZD1839), of epidermal growth factor receptor in refractory non-small-cell lung cancer 60
18F-FDG pet does not improve contrast enhanced CT scan sensitivity in the evaluation of liver metastases after chemotherapy 60
PREDICTIVE VALUE OF EARLY PET DURING SALVAGE CHEMOTHERAPY IN RELAPSING/REFRACTORY HODGKIN'S LYMPHOMA (HL) PATIENTS 60
Intensified CHOP in non-Hodgkin's lymphoma: What we know and what we need to know 59
Early lesions in lymphomas of germinal centre B-cell derivation: evidence and hypotheses. 59
Postoperative Chemoradiotherapy or Surgery Alone for Gastric Cancer: The Plausibility of the Question and Pertinence of the Answer 59
Early restaging positron emission tomography with 18 F-fluorodeoxyglucose in aggressive non-Hodgkin's lymphomas: is it too easy to be true? 59
Cerebrospinal fluid tumor DNA for liquid biopsy in glioma patients’ management: close to clinic 59
Outcome appraisal of patients with limited brain metastases (BMs) from non small cell lung cancer (NSCLC) treated with different local therapeutic strategies: a single institute evaluation. 58
A phase I clinical and pharmacokinetic study evaluating vinflumine in combination with epirubicin as first-line treatment in metastatic breast cancer 58
Advanced colorectal liver metastases and surgery after preoperative chemotherapy : is response-based selection enough? 57
Pilot study with adriamycin and ifosfamide in small cell lung cancer. 57
A Phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small cell lung cancer. 57
Can stereotactic body radiation therapy be a viable and efficient therapeutic option for unresectable locally advanced pancreatic adenocarcinoma? Results of a phase 2 study 56
A prospective study on survival in cancer patients with and without venous thromboembolism 56
Are three weeks hypofractionated radiation therapy (HFRT) comparable to six weeks for newly diagnosed glioblastoma patients? Results of a phase II study 56
Hypofractionated radiation therapy (HFRT) versus conventional fractionated radiation therapy (CRT) for newly diagnosed glioblastoma patients. A propensity score matched analysis. 55
Clinical Effects of Driver Somatic mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With allogeneic Hematopoietic Stem-Cell Transplantation 55
Genetic and epigenetic alterations in primary colorectal cancers and related lymph node and liver metastases 54
Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer 54
A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study 54
Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma 54
Aggressive and Multidisciplinary Local Approach to Iterative Recurrences of Colorectal Liver Metastases 54
High incidence of hypocalcemia and serum creatinine increase in patients with bone metastases treated with zoledronic acid 53
Fulvestrant for advanced male breast cancer patients: a case series 53
Association of Polymorphisms in AKT1 and EGFR with Clinical Outcome and Toxicity in Non-Small Cell Lung Cancer Patients Treated with Gefitinib 53
Weekly non-pegylated liposomal Doxorubicin chemotherapy in heavily pre-treated patients with metastatic breast cancer 53
Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Gemcitabine/Cisplatin Alone or With Sorafenib for the First-Line Treatment of Advanced, Nonsquamous Non-Small-Cell Lung Cancer. 53
Adjuvant volumetric modulated arc therapy compared to 3D conformal radiation therapy for newly diagnosed soft tissue sarcoma of the extremities: outcome and toxicity evaluation 53
Developing an adolescent and young adult (AYA) cancer program in an Italian adult high-volume cancer center. 53
Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications 53
Classical Hodgkin's lymphoma in adults: guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-up 53
Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy 53
A randomized study of lung cancer screening with spiral computed tomography: three-year results from the DANTE trial 53
A phase II study of the combination of gemcitabine and imatinib mesylate in pemetrexed-pretreated patients with malignant pleural mesothelioma 53
Initial chemotherapy for primary resectable large-cell lymphoma of the stomach 52
Trastuzumab beyond progression: a challenge to translational oncology? 52
COVID-19 and liver cancer clinical trials: not everything is lost 52
Carminomycin vs adriamycin in advanced soft tissue sarcomas: an EORTC randomised phase II study. 52
Ifosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcoma. The EORTC Soft Tissue and Bone Sarcoma Group 52
Response to Sunitinib in an Adult Patient With Rhabdoid Renal Cell Carcinoma 52
Utility of 18F-FDG PET and contrast-enhanced CT scan in the assessment of residual liver metastasis from colorectal cancer following adjuvant chemotherapy 52
Stereotactic body radiation therapy for lung metastases from soft tissue sarcoma. 52
Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1 in patients with hepatocellular carcinoma 52
New tricks for old biomarkers: thymidylate synthase expression as a predictor of pemetrexed activity in malignant mesothelioma 51
Second-line chemotherapy in malignant pleural mesothelioma: Results of a retrospective multicenter survey 51
Biomarkers in Hepatocellular Carcinoma-Letter 51
Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors 51
Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications 51
Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer 51
Minidose warfarin prophylaxis for catheter-associated thrombosis in cancer patients: Can it be safely associated with fluorouracil-based chemotherapy? 51
Ifosfamide and vinorelbine: an active regimen for patients with relapsed or refractory Hodgkin's disease 51
Lung resection for metastatic sarcomas: total survival from primary treatment. 51
Prognostic value of the immune-related transcriptome in biliary tract cancers 51
A phase II randomised (calibrated design) study on the activity of the single-agent trabectedin in metastatic or locally relapsed uterine leiomyosarcoma 51
Addition of temozolomide to radiotherapy for treatment of newly diagnosed anaplastic gliomas 51
FDG-PET as a tool to optimize residual surgery in patients with primary extragonadal germ cell tumors: preliminary results 51
Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach 51
Minidose warfarin is associated with a high incidence of International Normalized Ratio elevation during chemotherapy with FOLFOX regimen 51
The use of radiation therapy for oligoprogressive/oligopersistent oncogene driven non small cell lung cancer: state of the art 51
Administration of temozolomide during and after radiotherapy for newly diagnosed high-grade gliomas excluding glioblastoma multiforme 51
Assessment of prognostic factors in patients with metastatic epidural spinal cord compression (MESCC) from solid tumor after surgery plus radiotherapy: a single institution experience 51
A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer 51
EXTENDED-FIELD RADIOTHERAPY IN FAVORABLE STAGE IA-IIA HODGKINS-DISEASE (PROGNOSTIC ROLE OF STAGE) 50
Rituximab in thrombotic microangiopathy. 50
Targeted therapy for thymic epithelial tumors: a new horizon ? Review of the literature and two cases reports 50
Thyroid, pulmonary, and cardiac sequelae after treatment for Hodgkin's disease. 50
Bevacizumab combined with pemetrexed plus cisplatin followed by maintenance bevacizumab/pemetrexed as first-line treatment of advanced non-squamous non-small cell lung cancer: a single-arm Phase 2 study. 50
Chemotherapy with mitomycin c and capecitabine in patients with advanced colorectal cancer pretreated with irinotecan and oxaliplatin 50
A randomised phase II study on neo-adjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma 50
Changes in shedding of soluble tumor necrosis factor receptors (sR1/R2) and in dynamic MRI as early predictors of outcome with NGR-hTNF 50
A. Micrometastasis in sentinel (SLN) and non sentinel lymph nodes of breast cancer: an update including clinico-pathologic impact and survaival 50
A PHASE 1 SAFETY STUDY OF ONCOFID-P-B ADMINISTERED FOR 12 CONSECUTIVE WEEKS IN BCG UNRESPONSIVE/INTOLERANT PATIENTS WITH BLADDER CARCINOMA IN SITU (CIS): PRELIMINARY RESULTS 50
Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma 49
Thymoma associated with myasthenia and autonomic anti-Hu paraneoplastic neuropathy 49
Gene methylation in pleural mesothelioma : Correlations with clinico-pathological features and patient’s follow-up 49
Cabozantinib for the treatment of hepatocellular carcinoma 49
Current role of autologous and allogeneic stem cell transplantation for relapsed and refractory Hodgkin Lymphoma 49
Allogeneic peripheral stem-cell transplantation with reduced-intensity conditioning regimen in refractory primary B-cell prolymphocytic leukemia: a long-term follow-up 49
Standardisation of EGFR FISH in colorectal cancer: results of an international interlaboratory reproducibility ring study 49
Checkpoint inhibitors as treatment for malignant gliomas: "A long way to the top" 49
Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis 49
T-replete haploidentical allogeneic transplantation using post-transplantation cyclophosphamide in advanced AML and myelodysplastic syndromes 49
Totale 5.665
Salva come PNG Salva come JPEG
Categoria #
all - tutte 242.617
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 242.617
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020102 0 0 0 0 0 0 0 0 0 0 6 96
2020/202110.283 96 102 102 64 111 3.185 1.430 658 2.061 1.348 90 1.036
2021/20225.046 373 72 123 1.103 86 83 202 733 427 557 1.052 235
2022/202312.819 2.017 413 1.234 1.408 1.155 1.076 32 1.082 2.221 1.120 909 152
2023/20244.856 616 732 1.518 243 195 721 323 374 86 48 0 0
Totale 33.106